



February 3, 2021

C-Reveal is excited to announce that **Renato Skerlj, Ph.D., Elyse Bourque, Ph.D., and Feng Shi, Ph.D.** have joined the team.

"We are thrilled to have Renato, Elyse and Feng on board. They have been working together with members of the C-Reveal team for many years and are absolutely world class scientists and drug developers," said Thomas Haag, Ph.D., Co-Founder of C-Reveal. Dr. Skerlj and Dr. Bourque are veteran medicinal chemists and have worked together to create several successful therapeutics. Dr. Shi is one of the inventors of C-Reveal's technology and an expert in the mechanisms of PD-1/PD-L1 in inhibition and human CD8+T cell responses, such as activation, cytokine release, killing efficiency and proliferation. He completed post-doctoral fellowships at MIT and in Mark Cobbold's lab at the Harvard Medical School. He completed his Ph.D. at the Chinese Academy of Sciences in Beijing.

Dr. Skerlj has more than 25 years of experience leading the discovery and development of disease modifying small molecule drugs to treat genetically defined rare diseases. He has authored 67 publications, holds 52 patents and has advanced multiple drug candidates into clinical development. Dr. Skerlj served as Chief Scientific Officer for X4 Pharmaceuticals, Inc., where he also was one of the company's scientific founders and co-inventor of its lead drug candidate, mavorixafor. Prior to joining X4, Dr. Skerlj held leadership roles in drug discovery and development at Lysosomal Therapeutics where he co-invented LTI-291, a CNS drug in clinical development for Parkinson's disease. Previous to that, he was interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, a publicly traded company that was acquired by Genzyme in 2006. Dr. Skerlj is an accomplished drug developer with two approved drugs; plerixafor, a CXCR4-targeted stem cell mobilizer approved by the U.S. Food and Drug Administration (FDA) in 2008, and ertapenem, an anti-bacterial approved by the FDA in 2001. Dr. Skerlj received his Ph.D. in synthetic organic chemistry from the University of British Columbia, and completed postdoctoral fellowships at the University of Oxford and Ohio State University.

Dr. Bourque has over 15 years of pharmaceutical experience in drug discovery and development. As Associate Scientific Director at Genzyme she led medicinal chemistry programs for the rare diseases portfolio, resulting in the development of venglustat, a CNS-penetrant compound currently in Phase 2 for Fabry's disease. Elyse received her Ph.D. in Organic Chemistry from the University of Sherbrooke, Canada and completed a Postdoctoral Fellowship at the University of Leeds, United Kingdom.

About C-Reveal Therapeutics:

C-Reveal's proprietary technology, developed at Massachusetts General Hospital and Harvard University, helps the body's immune system to identify and destroy cancer cells by inhibiting key enzymes that conceal the disease. This patent pending approach is designed to improve the efficacy of treating a broad range of cancers. To learn more about the company, please visit: <https://crev.bio/>.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.